Our comprehensive drug discovery and development operation covers chemistry; biology; pharmacology; toxicology; manufacturing controls for clinical and commercial supply; clinical development; regulatory affairs; and other functions.
The growing scientific team now has about 900 scientists and staff in Shanghai, China and at our international clinical operation in New Jersey, U.S.A.
Through our international organization, based in New Jersey, we have rapidly expanded our clinical and regulatory capabilities in the U.S., Europe and now Japan.
We believe that the future of cancer and immunology treatments will continue to be a multi-pronged strategy, treating these diseases through multiple modalities and mechanisms.
We continue to further our pre-clinical programs for developing potential new medicines addressing aberrant genetic drivers and inactivated or insufficient T-cell response, as well as modifying the tumor microenvironment and the body's immune system.
We are focused on developing highly selective therapies that may offer: